ADAPY (Adaptimmune Therapeutics) Total Equity: $-70.96 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Total Equity?

Adaptimmune Therapeutics ADAPY +5.80% Total Equity is $-70.96 Mil as of Jun. 2025.

Adaptimmune Therapeutics's total equity for the quarter that ended in Jun. 2025 was $-70.96 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Adaptimmune Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Total Equity Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 341.23 205.96 81.88 39.51 11.85

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.27 79.99 11.85 -37.43 -70.96

Adaptimmune Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Adaptimmune Therapeutics's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=245.963-234.114
=11.85

Adaptimmune Therapeutics's Total Equity for the quarter that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=130.633-201.591
=-70.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-70.96 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Total Equity of $-70.96 Mil as of Jun. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Total Equity too high?
Adaptimmune Therapeutics' current Total Equity is $-70.96 Mil.
How does Adaptimmune Therapeutics' Total Equity compare to BCLI and APRE?
Adaptimmune Therapeutics' Total Equity of $-70.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Total Equity is $-70.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Total Equity of $-70.96 Mil. The current Total Equity is $-70.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Total Equity is $-70.96 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].